Search Videos and More

Showing 1 - 12 of 40 results

Previous| 1 | 2 | 3 ...4 |Next


Treatment Guidelines: Patients With a History of Breast Cancer who Desire Pregnancy Document

Treatment Guidelines: Patients With a History of Breast Cancer who Desire Pregnancy

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
Most Young Women Treated For Breast Cancer Can Have Children, Study Shows News

Most Young Women Treated For Breast Cancer Can Have Children, Study Shows

In a study of nearly 200 young women who have survived breast cancer, most of those who tried to conceive were able to become pregnant and give birth.
Breast Cancer Trial Aims to Improve Treatment for Men News

Breast Cancer Trial Aims to Improve Treatment for Men

Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer Document

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction News

Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction

Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer News

Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer

A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer Document

Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD Video

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD Video

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD Video

ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD

Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing News

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.

Showing 1 - 12 of 40 results

Previous| 1 | 2 | 3 ...4 |Next